Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022

Same author

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022

Same author

Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency.

Scientific reports·2018

Same author

The case for mandatory newborn screening for severe combined immunodeficiency (SCID).

Journal of clinical immunology·2014

Same author

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation.

Bone marrow transplantation·2014

Same author

Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.

Clinical and experimental immunology·2013

Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026

Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026

Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026

Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026

Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026

Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 11, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Current progress on gene therapy for primary immunodeficiencies.

L Zhang¹, A J Thrasher, H B Gaspar

¹Molecular Immunology Unit, Center for Immunodeficiency, Institute of Child Health, University College London, London, UK.

|May 31, 2013

Summary

This summary is machine-generated.

Gene therapy using viral vectors shows promise for treating primary immunodeficiencies (PIDs) by correcting bone marrow diseases. Advances in safer vector technology are improving efficacy and safety, potentially making gene therapy a standard PID treatment.

More Related Videos

Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

Published on: February 9, 2024

Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA

Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA

Published on: June 25, 2014

Related Experiment Videos

Last Updated: May 11, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

Suspension Culture Production and Purification of Adeno-Associated Virus by Iodixanol Density Gradient Centrifugation for In Vivo Applications

Published on: February 9, 2024

Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA

Linear Amplification Mediated PCR – Localization of Genetic Elements and Characterization of Unknown Flanking DNA

Published on: June 25, 2014

Area of Science:

* Hematology and Immunology
* Gene Therapy
* Molecular Biology

Background:

* Primary immunodeficiencies (PIDs) are monogenic bone marrow diseases.
* Gene therapy has shown success in correcting PIDs using ex vivo viral vector gene transfer into autologous hematopoietic stem cells.
* Early gene therapy studies faced challenges with vector-related insertional mutagenesis.

Purpose of the Study:

* To review the progress and challenges in gene therapy for PIDs.
* To highlight recent advancements in vector design and safety profiles.
* To discuss the future potential of gene therapy for PID treatment.

Main Methods:

* Review of ex vivo viral vector-mediated gene transfer into autologous hematopoietic stem cells.
* Analysis of safety profiles of alternative vector designs, including self-inactivating vectors.
* Examination of ongoing developments in gene correction technologies and cell transduction techniques.

Main Results:

* Gene therapy has demonstrated long-term disease correction for specific PIDs.
* Newer vector designs with self-inactivating features show improved safety profiles.
* Emerging studies indicate early signs of efficacy with advanced vector platforms.

Conclusions:

* Continued development of safer vector platforms and gene-correction technologies is crucial.
* Improvements in cell transduction and conditioning regimens will expand gene therapy's applicability to more PIDs.
* Gene therapy may become a standard treatment for specific PIDs if long-term efficacy and safety are established.